Enanta Pharmaceuticals announced positive topline results from a Phase IIa trial of EDP-323, its RSV replication inhibitor, ...
Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...
Enanta Pharmaceuticals has linked its respiratory syncytial virus (RSV) antiviral to significant reductions in viral load and ...
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), ...
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV ...
Watertown, Massachusetts Saturday, September 28, 2024, 18:00 Hrs [IST] ...
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug ...
Discover Enanta Pharmaceuticals' groundbreaking patent for HBV-inhibiting compounds, offering new hope for effective hepatitis B treatments and improved patient outcomes.
Check the time stamp on this data. Updated AI-Generated Signals for Enanta Pharmaceuticals Inc. (ENTA) available here: ENTA.
Check the time stamp on this data. Updated AI-Generated Signals for Enanta Pharmaceuticals Inc. (ENTA) available here: ENTA.
More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet. The new study by the Global Research ...